skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: An upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells with suppressive function through interleukin 2 pathway in pulmonary arterial hypertension

Abstract

Accumulating evidence suggests that abnormal inflammation plays a critical role in the pathogenesis of pulmonary arterial hypertension (PAH). CD8{sup +}CD25{sup +}Foxp3{sup +} T cell is a novel cell subtype, and its role in PAH is not yet investigated. Here, we observed that PAH patients presented a significant upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells and a downregulation of CD4{sup +}CD25{sup +}Foxp3{sup +} T cells compared to healthy controls. Regardless, the total number of CD25{sup +}Foxp3{sup +} T cells in PAH patients was still smaller than that in healthy controls. Compared to CD8{sup +}CD25{sup -} T cells, CD8{sup +}CD25{sup +} T cells presented higher Foxp3 expression, lower interferon (IFN)-γ expression and higher transforming growth factor (TGF)-β expression, in both healthy and PAH individuals. The CD8{sup +}CD25{sup +} T cells in PAH patients also demonstrated regulatory function by suppressing the proliferation of CD4{sup +}CD25{sup -} and CD8{sup +}CD25{sup -} effector T cells, albeit at lower efficiency than CD4{sup +}CD25{sup +} T cells from PAH patients and healthy volunteers. CD8{sup +}CD25{sup +} T cells from PAH responded to interleukin (IL)−2 supplement by expansion and upregulating Foxp3 expression. In PAH patients, IL-2-treated CD8{sup +}CD25{sup +} T cells were more potent at inhibiting CD4{supmore » +}CD25{sup -} effector T cell proliferation than IL-2-untreated CD8{sup +}CD25{sup +} T cells. Together, we found an upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells in PAH patients, and this T cell population presented suppressive activity that could be enhanced by IL-2 treatment.« less

Authors:
; ; ; ; ; ;
Publication Date:
OSTI Identifier:
22738154
Resource Type:
Journal Article
Journal Name:
Experimental Cell Research
Additional Journal Information:
Journal Volume: 358; Journal Issue: 2; Other Information: Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0014-4827
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; CELL PROLIFERATION; HYPERTENSION; PATIENTS; POLYCYCLIC AROMATIC HYDROCARBONS

Citation Formats

Zhu, Rong, Chen, Liang, Xiong, Yaqiong, Wang, Nana, Xie, Xiaochen, Hong, Yongqing, and Meng, Zili. An upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells with suppressive function through interleukin 2 pathway in pulmonary arterial hypertension. United States: N. p., 2017. Web. doi:10.1016/J.YEXCR.2017.06.017.
Zhu, Rong, Chen, Liang, Xiong, Yaqiong, Wang, Nana, Xie, Xiaochen, Hong, Yongqing, & Meng, Zili. An upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells with suppressive function through interleukin 2 pathway in pulmonary arterial hypertension. United States. doi:10.1016/J.YEXCR.2017.06.017.
Zhu, Rong, Chen, Liang, Xiong, Yaqiong, Wang, Nana, Xie, Xiaochen, Hong, Yongqing, and Meng, Zili. Fri . "An upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells with suppressive function through interleukin 2 pathway in pulmonary arterial hypertension". United States. doi:10.1016/J.YEXCR.2017.06.017.
@article{osti_22738154,
title = {An upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells with suppressive function through interleukin 2 pathway in pulmonary arterial hypertension},
author = {Zhu, Rong and Chen, Liang and Xiong, Yaqiong and Wang, Nana and Xie, Xiaochen and Hong, Yongqing and Meng, Zili},
abstractNote = {Accumulating evidence suggests that abnormal inflammation plays a critical role in the pathogenesis of pulmonary arterial hypertension (PAH). CD8{sup +}CD25{sup +}Foxp3{sup +} T cell is a novel cell subtype, and its role in PAH is not yet investigated. Here, we observed that PAH patients presented a significant upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells and a downregulation of CD4{sup +}CD25{sup +}Foxp3{sup +} T cells compared to healthy controls. Regardless, the total number of CD25{sup +}Foxp3{sup +} T cells in PAH patients was still smaller than that in healthy controls. Compared to CD8{sup +}CD25{sup -} T cells, CD8{sup +}CD25{sup +} T cells presented higher Foxp3 expression, lower interferon (IFN)-γ expression and higher transforming growth factor (TGF)-β expression, in both healthy and PAH individuals. The CD8{sup +}CD25{sup +} T cells in PAH patients also demonstrated regulatory function by suppressing the proliferation of CD4{sup +}CD25{sup -} and CD8{sup +}CD25{sup -} effector T cells, albeit at lower efficiency than CD4{sup +}CD25{sup +} T cells from PAH patients and healthy volunteers. CD8{sup +}CD25{sup +} T cells from PAH responded to interleukin (IL)−2 supplement by expansion and upregulating Foxp3 expression. In PAH patients, IL-2-treated CD8{sup +}CD25{sup +} T cells were more potent at inhibiting CD4{sup +}CD25{sup -} effector T cell proliferation than IL-2-untreated CD8{sup +}CD25{sup +} T cells. Together, we found an upregulation of CD8{sup +}CD25{sup +}Foxp3{sup +} T cells in PAH patients, and this T cell population presented suppressive activity that could be enhanced by IL-2 treatment.},
doi = {10.1016/J.YEXCR.2017.06.017},
journal = {Experimental Cell Research},
issn = {0014-4827},
number = 2,
volume = 358,
place = {United States},
year = {2017},
month = {9}
}